Lexicon’s LX9211 Shows Significant And Consistent Benefits In The Treatment Of Painful Diabetic Neuropathy In Full Results From The Phase 2 RELIEF-DPN-1 Trial Presented At The 16th Annual Pain Therapeutics Summit

  Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6 Significant benefits demonstrated on burning pain and on pain interference with sleep No evidence of withdrawal symptoms or

 

  • Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6
  • Significant benefits demonstrated on burning pain and on pain interference with sleep
  • No evidence of withdrawal symptoms or rebound pain after treatment ended
Total
0
Shares
Related Posts